Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes. It has license agreements with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Frequently asked questions
What sector does Aptose Biosciences Inc (APS) operate in?
Aptose Biosciences Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Aptose Biosciences Inc (APS) current stock price?
As of the latest data, Aptose Biosciences Inc stock price is CA$2.40, with a previous close of CA$2.40.
What is Aptose Biosciences Inc (APS) current market capitalization?
Aptose Biosciences Inc market cap is approximately 6.13 million.
What is Aptose Biosciences Inc (APS) Earnings Per Share (EPS)?
The trailing EPS is -CA$14.78, and the forward EPS is -CA$5.65.
Does Aptose Biosciences Inc (APS) pay dividends?
No. Aptose Biosciences Inc does not pay a dividend.
What is Aptose Biosciences Inc (APS) beta (volatility) score?
Aptose Biosciences Inc has a beta of 0.344, indicating lower volatility than the overall market.